Spots Global Cancer Trial Database for Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Official Title: Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Study ID: NCT02338531
Conditions
Study Description
Brief Summary: This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic triple-negative breast cancer patients with residual disease (cHEmoresistant) after completion of standard neoadjuvant chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Institut Jules Bordet, Brussels, , Belgium
Grand Hopital de Charleroi, Charleroi, , Belgium
CMSE, Namur, , Belgium
Institut Curie, Paris, , France
Institut de Cancérologie Gustave Roussy, Villejuif, , France
Contact Details
Name: Michail Ignatiadis, MD, PhD
Affiliation: Medical Oncology Department
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
